Eli Lilly’s strategic pivot toward oral GLP-1 agonists such as orforglipron, combined with its June 2025 licensing of Camurus’ FluidCrystal long-acting injectable platform, has tilted trader sentiment against a near-term commercial license for Peptron’s SmartDepot sustained-release microsphere technology. The original October 2024 evaluation agreement was extended in December 2025 through October 7, 2026, to allow further in-vivo studies on Lilly’s peptide candidates, yet no technology-transfer announcement has occurred despite ongoing joint research. With roughly five months remaining until the resolution date, traders view the absence of a binding commercial deal as the dominant factor supporting the current 55% implied probability on “No.”
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
ใหม่
ใหม่
Oct 7, 2026
ใหม่
ใหม่
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s strategic pivot toward oral GLP-1 agonists such as orforglipron, combined with its June 2025 licensing of Camurus’ FluidCrystal long-acting injectable platform, has tilted trader sentiment against a near-term commercial license for Peptron’s SmartDepot sustained-release microsphere technology. The original October 2024 evaluation agreement was extended in December 2025 through October 7, 2026, to allow further in-vivo studies on Lilly’s peptide candidates, yet no technology-transfer announcement has occurred despite ongoing joint research. With roughly five months remaining until the resolution date, traders view the absence of a binding commercial deal as the dominant factor supporting the current 55% implied probability on “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 5, 2026, 8:02 PM ET
ปริมาณการซื้อขาย
$8,308วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s strategic pivot toward oral GLP-1 agonists such as orforglipron, combined with its June 2025 licensing of Camurus’ FluidCrystal long-acting injectable platform, has tilted trader sentiment against a near-term commercial license for Peptron’s SmartDepot sustained-release microsphere technology. The original October 2024 evaluation agreement was extended in December 2025 through October 7, 2026, to allow further in-vivo studies on Lilly’s peptide candidates, yet no technology-transfer announcement has occurred despite ongoing joint research. With roughly five months remaining until the resolution date, traders view the absence of a binding commercial deal as the dominant factor supporting the current 55% implied probability on “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$8,308วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s strategic pivot toward oral GLP-1 agonists such as orforglipron, combined with its June 2025 licensing of Camurus’ FluidCrystal long-acting injectable platform, has tilted trader sentiment against a near-term commercial license for Peptron’s SmartDepot sustained-release microsphere technology. The original October 2024 evaluation agreement was extended in December 2025 through October 7, 2026, to allow further in-vivo studies on Lilly’s peptide candidates, yet no technology-transfer announcement has occurred despite ongoing joint research. With roughly five months remaining until the resolution date, traders view the absence of a binding commercial deal as the dominant factor supporting the current 55% implied probability on “No.”
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย